Skip to main content

Please select
your location below

Attenzione, le pagine di questa sezione sono disponibili solo in lingua inglese.

By selecting the International view, you verify that you reside outside of the USA and you wish to view DiaSorin Molecular’s International Product Information. This material is intended for International (non-USA) site visitors only.

Pursuant to the Guidelines of the Ministry of Health dated 28/03/2013 related to health advertising concerning medical devices, in vitro diagnostic medical devices and medical-surgical devices, we hereby inform you that the information contained in this website and to which you are going to access is exclusively intended for professionaloperators.

xTAG® CYP2C19 Kit v3

Help clinicians identify mutations indicative of adverse effects with certain drugs

xTAG CYP2C19 is a highly scalable genetic test with clinically relevant mutations.


Disease state

Cytochrome P450 2C19 (CYP2C19) metabolize 5% of the prescription drugs in use today.  Genotypic variants of CYP2C19 change how these drugs are metabolized.  CYP2C19*2 and CYP2C19*3 variants account for approximately 99% of Asian and 87% of Caucasians poor metabolizers, respectively. Over one-third of Caucasians and over 40% of patients of African and Asian ancestry harbor gain-of-function and loss-of-function 2C19 variants. These variants are linked to a higher risk of adverse events with certain drugs. 

CYP2C19 mutations are potential indicators of poor drug metabolism

The value of xTAG® CYP2C19 Kit v3

Empower clinicians to accurately identify clinically relevant CYP2C19 mutations: CYP2C19*2, CYP2C19*3, and CYP2C19*17.


Detect and identify clinically relevant genotypes.

Resource efficient

Obtain flexibility in throughput with Luminex® 200™ platform and MAGPIX® instrument.


Gain confidence in results with high accuracy and reproducibility.

How the xTAG® CYP2C19 Kit v3 test works

xTAG® CYP2C19 Kit v3 is a multiplexed nucleic acid test intended for the detection of clinically relevant mutations *2, *3, *17.


High complexity workflow

Nucleic acid extraction and purification, multiplex amplification, bead hybridization and detection, and data acquisition and analysis by MAGPIX® or Luminex® 200™ with xPONENT® software.


Time to results

Within 8 hours, a laboratory can detect and determine the relevant genotypes for their clients.

Indications for xTAG® CYP2C19 Kit v3 Test use

Assay and system

A multiplexed nucleic acid test for the detection of 2C19 from EDTA and Citrate Blood.

xTAG® CYP2C19 Kit v3

The xTAG® CYP2C19 is multiplex PCR and multiplex Allele Specific Primer Extension (ASPE) on Luminex platforms that automatically determines diplotype.






For use with the MAGPIX® or Luminex® 200™ Systems with xPONENT®

xTAG® CYP2C19 Kit v3 Test rapidly and accurately detects relevant mutations via the MAGPIX® or Luminex® 200TM systems with xPONENT® software.

Delivery of this time-critical information allows clinicians to provide targeted patient care more quickly.

xTAG® CYP2C19 Kit v3 Test makes it a valuable system for use in specialized laboratories with high-complexity testing capabilities.

Molecular Diagnostics Tool MAGPIX® System - Diasorin

MAGPIX® System

High throughput multiplex platform.

Discover more

xTAG® CYP2C19 Kit v3 ordering info

Part Name
Kit Size
Registration Status
Part Number

xTAG® CYP2C19 Kit v3

48 tests




Diasorin document repository


Luminex document repository

Discover more

Research publications

Discover more

More details about xTAG® CYP2C19 Kit v3

Get in touch

If you need any information about our products, contact our specialists. 

Contact us

Need any help?

Get help with Diasorin products and services.

Ask for support